The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2024 | The SUMMIT trial: bezuclastinib in adult patients with non-advanced systemic mastocytosis
Prithviraj Bose, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the ongoing Phase II SUMMIT trial (NCT05186753) investigating bezuclastinib, a potent and selective KIT D816V inhibitor, for adult patients with non-advanced systemic mastocytosis, including indolent and smoldering forms. The study has progressed to a placebo-controlled phase following the identification of the optimal dose, with promising efficacy and reduction in disease burden markers. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research support: Incyte, BMS, CTI (Sobi), Morphosys, Karyopharm, Sumitomo, Ajax, Disc, Ionis, Geron, Janssen, Cogent, Blueprint, Kartos, Telios.; Honoraria/consulting fees: Incyte, BMS, CTI (Sobi), GSK, Abbvie, Morphosys, Pharma Essentia, Sumitomo, Karyopharm, Ionis, Disc, Geron, Morphic, Jubilant, Ono, Novartis, Blueprint, Cogent.
